Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 40 Glioma 17 Brain Neoplasms 14 Astrocytoma 11 Neuroblastoma 10 Gliosarcoma 10 Neoplasms 8 Sarcoma, Ewing 7 Rhabdomyosarcoma 6 Recurrence 5 Oligodendroglioma 5 Sarcoma 4 Medulloblastoma 4 Neoplasm Metastasis 3 Diffuse Intrinsic Pontine Glioma 3 Wilms Tumor 2 Small Cell Lung Carcinoma 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Melanoma 2 Lymphoma, Follicular 2 Hepatoblastoma 2 Central Nervous System Neoplasms 2 Spinal Cord Neoplasms 1 Somatostatinoma 1 Rhabdoid Tumor 1 Refractory Solid Tumors 1 Pyloric Stenosis, Hypertrophic 1 Prostatic Neoplasms 1 Pheochromocytoma 1

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × Temozolomide × 90 days × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡